Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAG | P20916 | 7/20 | 0.50 |
| ▸ | SIGLEC7 | Q9Y286 | 6/20 | 0.48 |
| ▸ | SELE | P16581 | 4/20 | 0.47 |
| ▸ | SELL | P14151 | 2/20 | 0.43 |
| ▸ | SELP | P16109 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16342337 | 1.00 | MAG (0.50) | MAGSIGLEC7SELESELLSELP | |
| SCHEMBL16187918 | 1.00 | MAG (0.50) | MAGSIGLEC7SELESELLSELP | |
| SCHEMBL25446563 | 1.00 | MAG (0.50) | MAGSIGLEC7SELESELLSELP | |
| SCHEMBL16187872 | 1.00 | MAG (0.50) | MAGSIGLEC7SELESELLSELP | |
| SCHEMBL12197077 | 0.95 | MAG (0.48) | MAGSIGLEC7SELESELLSELP | |
| SCHEMBL4119673 | 0.95 | MAG (0.48) | MAGSIGLEC7SELESELLSELP | |
| SCHEMBL17195861 | 0.95 | MAG (0.48) | MAGSIGLEC7SELESELLSELP | |
| SCHEMBL15849102 | 0.95 | MAG (0.48) | MAGSIGLEC7SELESELLSELP | |
| SCHEMBL16232780 | 0.95 | MAG (0.48) | MAGSIGLEC7SELESELLSELP | |
| SCHEMBL16312032 | 0.95 | MAG (0.48) | MAGSIGLEC7SELESELLSELP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8765669-B2 | Glycosylated GLP-1 peptide | GLYTECH, INC. (JP) | 2014-07-01 | — | — | US | disclosed |
| US-8507429-B2 | Sugar chain added GLP-1 peptide | GLYTECH, INC. (JP) | 2013-08-13 | — | — | US | disclosed |
| US-20120264684-A1 | Glycosylated Form of Antigenic GLP-1 Analogue | GLYTECH, INC. (JP) | 2012-10-18 | — | — | US | disclosed |
| US-20110245166-A1 | SUGAR CHAIN ADDED GLP-1 PEPTIDE | OTSUKA CHEMICAL HOLDINGS CO., LTD (JP) | 2011-10-06 | — | — | US | disclosed |
| US-20110195897-A1 | GLYCOSYLATED GLP-1 PEPTIDE | OTSUKA CHEMICAL CO., LTD. (JP) | 2011-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110195897-A1 | GLYCOSYLATED GLP-1 PEPTIDE | GLP1R, GIPR, IAPP | MAG 1399/4885SIGLEC7 102/4885SELE 200/4885 |
| US-20110245166-A1 | SUGAR CHAIN ADDED GLP-1 PEPTIDE | GLP1R, IAPP, GIPR | MAG 1836/4885SIGLEC7 308/4885SELE 158/4885 |
| US-20120264684-A1 | Glycosylated Form of Antigenic GLP-1 Analogue | GLP1R, GIPR, IAPP | MAG 341/4885SIGLEC7 414/4885SELE 670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.